8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Dec 8, 2025·SEC
Arcutis Biotherapeutics, Inc.(ARQT)Earnings, Financials & Key Ratios
ARQT•NASDAQ
$27.67
Price updated Jul 7, 2026
AboutArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Show more
- Revenue$376M+91.3%
- EBITDA-$7M+94.5%
- Net Income-$16M+88.5%
- EPS (Diluted)-0.13+88.8%
- Gross Margin90.24%
- EBITDA Margin-1.82%+97.2%
- Operating Margin-3.25%+95.0%
- Net Margin-4.29%+94.0%
- ROE-9.3%+91.8%
ARQT Price & Volume
Arcutis Biotherapeutics, Inc. (ARQT) stock price & volume — 10-year historical chart
Loading chart...
Volatile Commercial Scaling Masks Liquidity Funding Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Arcutis Biotherapeutics demonstrates significant pricing power with gross margins consistently exceeding 90%, yet the company struggles to achieve sustainable operating leverage as SG&A expenses frequently track closely with revenue growth.
- While the firm has successfully reduced total debt from $205.9M in 2023Q4 to $13.2M in 2026Q1, the rapid depletion of cash reserves to $34.8M suggests a precarious liquidity position.
- Investors should monitor whether the company can stabilize its volatile revenue trajectory, which saw growth decelerate from 164.1% in 2025Q2 to 60.1% in 2026Q1, without resorting to further dilutive financing.
Verdict Logic
while the company exhibits strong product pricing power with 90.7% gross margins, the dwindling cash balance of $34.8M and the history of volatile revenue growth suggest significant execution and liquidity risks.
ARQT Growth Metrics
Arcutis Biotherapeutics, Inc. (ARQT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years367.27%
TTM95.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM98.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM96.71%
Return on Capital
10 Years-66.24%
5 Years-51.69%
3 Years-39.4%
Last Year-4.28%
ARQT Recent Earnings
Arcutis Biotherapeutics, Inc. (ARQT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.09-350.0%
$0.02
Rev
$105M+1.7%
$104M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.13+333.3%
$0.03
Rev
$130M+14.5%
$113M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.06+160.0%
$0.10
Rev
$99M-10.4%
$111M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.13+27.8%
$0.18
Rev
$82M+1.1%
$81M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.09vs $0.02-350.0% | $105Mvs $104M+1.7% |
| Q1 2026 | Feb 25, 2026 | $0.13vs $0.03+333.3% | $130Mvs $113M+14.5% |
| Q4 2025 | Oct 28, 2025 | $0.06vs $0.10+160.0% | $99Mvs $111M-10.4% |
| Q3 2025 | Aug 6, 2025 | $0.13vs $0.18+27.8% | $82Mvs $81M+1.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Arcutis Biotherapeutics, Inc. (ARQT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.67 | $3.46B | -212.85 | 91.34% | -4.29% | -9.3% | — | |
| $6.75 | $185.63M | -14.35 | 10.2% | -14.82% | -35.57% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Compare ARQT vs Peers
Arcutis Biotherapeutics, Inc. (ARQT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARQT SEC Filings & Documents
Arcutis Biotherapeutics, Inc. (ARQT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ARQT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARQT Frequently Asked Questions
Arcutis Biotherapeutics, Inc. (ARQT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Arcutis Biotherapeutics, Inc.'s revenue?
Arcutis Biotherapeutics, Inc. (ARQT) reported $415.6M in revenue for fiscal year 2025.
How fast is Arcutis Biotherapeutics, Inc. growing?
Arcutis Biotherapeutics, Inc. (ARQT) grew revenue by 91.3% over the past year. This is strong growth.
Is ARQT profitable?
Arcutis Biotherapeutics, Inc. (ARQT) reported a net loss of $2.4M for fiscal year 2025.
Dividend & Returns
What is ARQT's return on equity?
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity (ROE) of -9.3%. Negative ROE indicates the company is unprofitable.
What is Arcutis Biotherapeutics, Inc.'s free cash flow?
Arcutis Biotherapeutics, Inc. (ARQT) generated $26.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.